{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:44:16Z","timestamp":1772631856267,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019827","name":"Atrium Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clml.2024.12.001","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T02:08:24Z","timestamp":1733969304000},"page":"e200-e209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Vaz","family":"Pinto Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Manoel Marques","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-2421","authenticated-orcid":false,"given":"Angela Marie","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Jose Pessoa de Magalh\u00e3es","family":"Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Vieira","family":"Pericole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri","family":"Sanku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.12.001_bib0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0002","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.12.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101143","article-title":"Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action","volume":"33","author":"Wudhikarn","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2024.12.001_bib0004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.21115\/JBES.v10.n2.p165-171","article-title":"Unmet needs in multiple myeloma in Brazil from physicians\u2019 perspective \u2013 barriers in quality of life and disease management","volume":"10","author":"Maiolino","year":"2018","journal-title":"Jornal Brasileiro de Economia da Sa\u00fade"},{"key":"10.1016\/j.clml.2024.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0006","unstructured":"Altekruse S, Kosary C, Karpcho M, et al: SEER cancer statistics review, 1975-2007 Bethesda, MD, NCI, 2010. Available from: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2007\/results_merged\/sect_18_myeloma.pdf. Accessed 5 January 2025."},{"key":"10.1016\/j.clml.2024.12.001_bib0007","first-page":"1","article-title":"Challenges and opportunities to access innovation in latin america: the case of combination therapies for multiple myeloma","volume":"3","author":"Delgado","year":"2022","journal-title":"RAS Oncol Ther"},{"key":"10.1016\/j.clml.2024.12.001_bib0008","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/cam4.1347","article-title":"Epidemiology of multiple myeloma in 17 Latin American countries: an update","volume":"7","author":"Curado","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0009","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0010","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.001_bib0011","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0012","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.001_bib0013","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/16078454.2022.2112643","article-title":"Multiple myeloma in Latin America","volume":"27","author":"G\u00f3mez-Almaguer","year":"2022","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2024.12.001_bib0014","unstructured":"CONITEC. Diretrizes Diagn\u00f3sticas e Terap\u00eauticas do Mieloma M\u00faltiplo 2022. Brazil. National Committee for Technology Incorporation. 2022. Available from: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/consultas\/relatorios\/2022\/20220526_ddt_mieloma_multiplo_cp.pdf. Accessed 21 May 2024."},{"key":"10.1016\/j.clml.2024.12.001_bib0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.htct.2022.06.003","article-title":"Guidelines on the diagnosis and management of multiple myeloma treatment: Associac ao Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associa\u00e7\u00e3o M\u00e9dica Brasileira - 2022","volume":"44","author":"Maiolino","year":"2022","journal-title":"Part I. Hematol, Transfusion Cell Ther"},{"key":"10.1016\/j.clml.2024.12.001_bib0016","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2024.12.001_bib0017","doi-asserted-by":"crossref","first-page":"1197340","DOI":"10.3389\/fonc.2023.1197340","article-title":"Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma","volume":"13","author":"Rosi\u00f1ol","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0018","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.12.001_bib0019","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.001_bib0020","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0021","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.12.001_bib0022","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0023","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0024","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2016.68.6113","article-title":"Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalized approach","volume":"34","author":"Larocca","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.12.001_bib0026","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0027","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(19)31711-8","article-title":"Surrogate endpoints in randomised controlled trials: a reality check","volume":"394","author":"Kumar","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.12.001_bib0028","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0029","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.12.001_bib0030","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0031","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0032","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0033","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/cancers15082203","article-title":"Current main topics in multiple myeloma","volume":"15","author":"Mor\u00e8","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.12.001_bib0034","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.001_bib0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967676.59550.94","article-title":"S191: Pivotal Phase 2 monumental-1 results of Talquetamab (TAL), a gprc5dxcd3 bispecific antibody (BSAB), for relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Touzeau","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.12.001_bib0037","doi-asserted-by":"crossref","first-page":"e20021","DOI":"10.1200\/JCO.2023.41.16_suppl.e20021","article-title":"Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1","volume":"41","author":"Tomasson","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0038","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/CCO.0000000000000983","article-title":"T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA","volume":"35","author":"van de Donk","year":"2023","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0039","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0040","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.3390\/cancers15184550","article-title":"Bispecific antibodies in hematological malignancies: a scoping review","volume":"15","author":"Omer","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2024.12.001_bib0041","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jha2.729","article-title":"T-cell redirecting bispecific antibodies in multiple myeloma: current landscape and future directions","volume":"4","author":"O'Neill","year":"2023","journal-title":"eJHaem"},{"key":"10.1016\/j.clml.2024.12.001_bib0042","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2024.12.001_bib0043","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum David","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0044","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.12.001_bib0045","unstructured":"Food and Drug Administration. 2023. TALVEY\u2122 (talquetamab-tgvs) injection, for subcutaneous use. Highlights of prescribing information, 2023. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf. Accessed 7 January 2025."},{"key":"10.1016\/j.clml.2024.12.001_bib0046","unstructured":"Food and Drug Administration. 2022. TECVAYLI\u2122 (teclistamab-cqyv) injection, for subcutaneous use. highlights of prescribing information. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf. Accessed 7 January 2025."},{"key":"10.1016\/j.clml.2024.12.001_bib0047","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0048","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.12.001_bib0049","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.12.001_bib0050","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.clml.2024.12.001_bib0051","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.3390\/cancers15112948","article-title":"Belantamab mafodotin: from clinical trials data to real-life experiences","volume":"15","author":"Mor\u00e8","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.12.001_bib0052","article-title":"Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Trude","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0053","doi-asserted-by":"crossref","first-page":"e20049","DOI":"10.1200\/JCO.2023.41.16_suppl.e20049","article-title":"Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies","volume":"41","author":"Patel","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.12.001_bib0054","first-page":"119","article-title":"CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphatic Cancer: Targets Ther"},{"key":"10.1016\/j.clml.2024.12.001_bib0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.001_bib0056","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.12.001_bib0057","unstructured":"CARVYKTITUM package insert. Available from: https:\/\/www.fda.gov\/media\/156560\/download. Accessed 7 January 2025."},{"key":"10.1016\/j.clml.2024.12.001_bib0058","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.12.001_bib0059","first-page":"2023","article-title":"Clinical outcomes of subsequent therapies in patients with relapsed\/refractory multiple myeloma following talquetamab treatment: analyses from the phase 1\/2 monumental-1 study","volume":"142","author":"Sanchez","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.001_bib0060","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1097\/01.HS9.0000850804.18842.41","article-title":"PB1993: multiple myeloma brazilian register- how about the transplant eligible patients?","volume":"6","author":"Crusoe","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.12.001_bib0061","unstructured":"Janssen: TALVEY\u00ae (talquetamabe), 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf. Accessed 7 January 2025."},{"key":"10.1016\/j.clml.2024.12.001_bib0062","unstructured":"ANVISA: Elrexfio\u00ae (elranatamab): new registration, 2023. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/novos-medicamentos-e-indicacoes\/elrexfio-r-elranatamabe-novo-registro. Accessed 7 January 2025."},{"key":"10.1016\/j.clml.2024.12.001_bib0063","unstructured":"ANVISA: Tecvayli (teclistamab): new registration, 2023. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2024\/anvisa-divulga-resultados-do-projeto-orbis. Accessed 7 January 2024."},{"key":"10.1016\/j.clml.2024.12.001_bib0064","unstructured":"Presidentt of the Republic. Brazil. Law No. 9. June 3, 1998. [website] https:\/\/www.planalto.gov.br\/ccivil_03\/leis\/l9656.htm#:~:text=LEI%20N%C2%BA%209.656%2C%20DE%203%20DE%20JUNHO%20DE%201998. Accessed 20 May 2024."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502402442X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502402442X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:38:20Z","timestamp":1772606300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502402442X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S215226502402442X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}